Related Experiment Video
Updated: Oct 14, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid lowering in patients 75 years and older
Umidakhon Makhmudova1, P Christian Schulze1, Harry R Davis2
1Klinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany.
Abstract:
More than twenty years ago, knowledge about the importance of cholesterol absorption and the potential therapeutic effect of its inhibition led to the discovery and clinical application of the first and only cholesterol absorption inhibitor to date - ezetimibe. Since then, ezetimibe has become a well-recognized player in lipid-lowering therapy. Recent findings of IMPROVE-IT and EWTOPIA 75 imply that elderly patients over the age of 75 years in particular benefit from ezetimibe. This review summarizes the evidence, discusses the possible underlying pathophysiological mechanisms and calls for a change in future dyslipidemia guidelines.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Atherosclerosis III: Management
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

